Previous 10 | Next 10 |
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancrea...
Nabriva Therapeutics plc (NBRVF) is expected to report for Q2 2023 JFE Holdings, Inc. (JFEEF) is expected to report for Q1 2024 Superior Gold Inc (SUPGF) is expected to report for Q2 2023 S&W Seed Company (SANW) is expected to report $-0.09 for Q4 2023 Jefferies Financial Grou...
Propanc Biopharma Inc (PPCB) is expected to report for quarter end 2023-06-30
Initial Discussion Held with Clinical Investigator at Australia’s Biggest Cancer Hospital Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients sufferi...
Increased Emphasis on R&D in Molecular Biology by Private and Public Players will Provide Lucrative Opportunities in the Pancreatic Cancer Market Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company de...
Reader interest above 93% of published research articles over the past year Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that synthetic recombinant proenzymes trypsinogen and ...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s board of directors (the ...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP suppresses the TGF-β pathway and the t...
News, Short Squeeze, Breakout and More Instantly...
Propanc Biopharma Inc Company Name:
PPCB Stock Symbol:
OTCMKTS Market:
Propanc Biopharma Inc Website:
British Journal of Cancer Concludes Tumor cell-intrinsic PD-L1 function promotes EMT Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recu...
Certificate of Grant Received for “Cancer Treatment” Patent from IP Corporation of Malaysia Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patient...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s &...